Pro-Dex, Inc. (PDEX)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$63.44+5.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · PDEX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.3% |
| Our one-year growth estimate | diamond | 5.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 33.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
PDEX — CEO transition
Dated 2026-08-28
CFO — Alisha K. Charlton: The filing discloses a discretionary bonus payment to the CEO and CFO, which is a compensation arrangement rather than a change in management personnel.
Why it matters: The next-generation handpiece drove much of recent sales growth. Its sales were about $9.8 million in fiscal 2026.
Supportive ifA later filing reports over $10 million in next-gen handpiece sales in one quarter. That is above the fiscal 2026 quarterly average of about $9.8 million.
Worry ifA later filing reports next-gen handpiece sales below the fiscal 2026 quarterly average of $9.8 million. Or it says gains were offset by legacy repairs.
Why it matters: Gross margin reached 33% in Q1 FY2027, up from 29% a year earlier. A drop could show that the favorable product mix has faded.
Watch forThe next quarterly report shows gross margin at or above 33%, matching or topping Q1 FY2027.
Also watch forThe next quarterly report shows gross margin below 29%, below both Q1 FY2027 and the year-earlier quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$207 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $514 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,147 loss on $10,000 · 21.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.